ASF1B promotes cervical cancer progression through stabilization of CDK9

Liu, Xinjian; Song, Jingwei; Zhang, Yenan; Wang, Huiquan; Sun, Hongmei; Feng, Xiaomin; Hou, Min; Guo, Chen; Tang, Qi; Ji, Minjun

doi:10.1038/s41419-020-02872-5

Cited by 60 publications

(69 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Up-regulated ASF1B expression has been related to a higher risk of disease growth, cancer progression, and metastasis in small breast cancer [10]. Silencing ASF1B in prostate cancer blocked replication, cell cycle arrest, and induced apoptosis, while knocking down ASF1B in cervical cancer was linked to proliferation, migration, and anti-apoptosis [11]. ASF1A and ASF1B were found to be strongly expressed in both LUAD and LUSC samples in the current research.…”

Section: Discussionsupporting

confidence: 48%

“…ASF1B could also control proliferation and P53 signaling pathways, according to GSEA and KEGG pathway enrichment studies. ASF1B was shown to encourage proliferation in small breast cancer, prostate cancer, and cervical cancer in previous studies [10][11][12][13]. As a result, we hypothesized that ASF1B may play a role in lung adenocarcinoma proliferation and metastasis.…”

Section: Discussionmentioning

confidence: 82%

“…ASF1B was shown to be linked to cervical cancer migration [11]. Therefore, we hypothesized that ASF1B was involved in lung adenocarcinoma migration.…”

Section: Discussionmentioning

confidence: 97%

“…ASF1A and ASF1B is the two members of ASF1, which controls chromatin functions and has been linked to tumorigenesis [7,9,10,17]. However, only several reports have stated the role of ASF1B in tumor, about prostate cancer, breast cancer, and cervical cancer [10][11][12][13]. Therein, we have identi ed ASF1B function as an oncogene in NSCLC through the combination of bioinformatic analysis, molecular biology and cell biological experiments.…”

Section: Discussionmentioning

confidence: 99%

“…A previous study of Armelle et al discovered that an elevated ASF1B mRNA level was linked to clinical evidence and disease outcome in breast cancer, and the researchers suggested that ASF1B may be used as a potential proliferation marker for breast cancer detection and prognosis [10]. XJ Liu et al identi ed ASF1B promote proliferation and migration in cervical cancer cells, and it could be used as prognostic factor in cervical cancer patients [11]. GY Han et al…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Aberrantly ASF1B Promotes Proliferation and Metastasis of Lung Adenocarcinoma in Vitro Study

2021

Preprint

View full text Add to dashboard Cite

ASF1A and ASF1B are two isoforms of the histone H3–H4 chaperone anti-silencing feature 1 (ASF1) found in mammalian cells. To date, however, it remains elusive if they have different physiological functions in lung adenocarcinoma. Here, we identified both ASF1A and ASF1B are elevated in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). ASF1B, but not ASF1A is associated with poor clinical outcomes and act as an independent prognostic factor in LUAD. In vitro studies, knockdown of ASF1B inhibits the proliferation of lung adenocarcinoma through modulating the expression of cyclins and CDK inhibitor (CKI). Moreover, by restraining epithelial-mesenchymal transition (EMT), abnormal of ASF1B could limit metastasis of lung adenocarcinoma. In summary, ASF1B is important in the development of NSCLC and can provide a novel target for lung cancer therapy.

show abstract

Section: Discussionsupporting

confidence: 48%

Section: Discussionmentioning

confidence: 82%

“…ASF1B was shown to be linked to cervical cancer migration [11]. Therefore, we hypothesized that ASF1B was involved in lung adenocarcinoma migration.…”

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Aberrantly ASF1B Promotes Proliferation and Metastasis of Lung Adenocarcinoma in Vitro Study

2021

Preprint

View full text Add to dashboard Cite

show abstract

Comprehensive analysis of pan‐cancer reveals potential of ASF1B as a prognostic and immunological biomarker

Zhu

Zhang

et al. 2021

Cancer Medicine

View full text Add to dashboard Cite

Background Anti‐silencing function 1 (ASF1) is a conserved histone H3–H4 chaperone protein. ASF1B, a paralog of ASF1, acts by promoting cell proliferation and influencing cell cycle progression. Although there is some evidence demonstrating that ASF1B plays a key role in the development, progression, and prognosis of certain cancers, there are no pan‐cancer analyses of ASF1B. Methods We used a range of bioinformatics approaches to investigate the predictive role of ASF1B, including its correlation with prognosis, tumor mutational burden (TMB), microsatellite instability (MSI), tumor microenvironment (TME), and immune cell infiltration, in diverse cancer types. Results We found that ASF1B was highly expressed in 22 cancers and was negatively correlated with the prognosis of multiple major cancer types. Furthermore, ASF1B expression was correlated with TMB in 21 cancers and with MSI in 7 cancers. We found that ASF1B was coexpressed with genes encoding immune activators, immune suppressors, major histocompatibility complexes, chemokines, and chemokine receptors. We further found that the role of ASF1B in the infiltration of different types of immune cells varied across tumor types. ASF1B may potentially affect several key immune‐related pathways, such as those involved in antigen processing and presentation, natural killer cell‐mediated cytotoxicity, and autoimmune thyroid disease. Conclusions Our findings show that ASF1B may serve as a prognostic marker and potential immunotherapeutic target for several malignancies due to its role in tumorigenesis and immune infiltration.

show abstract

Effects of Metformin on the virus/host cell crosstalk in human papillomavirus‐positive cancer cells

Hoppe‐Seyler

Herrmann

Däschle

et al. 2021

Intl Journal of Cancer

View full text Add to dashboard Cite

Oncogenic types of human papillomaviruses (HPVs) are major human carcinogens. The viral E6/E7 oncogenes maintain the malignant growth of HPV-positive cancer cells. Targeted E6/E7 inhibition results in efficient induction of cellular senescence, which could be exploited for therapeutic purposes. Here we show that viral E6/E7 expression is strongly downregulated by Metformin in HPV-positive cervical cancer and head and neck cancer cells, both at the transcript and protein level. Metformininduced E6/E7 repression is glucose and PI3K-dependent but-other than E6/E7 repression under hypoxia-AKT-independent. Proteome analyses reveal that Metformin-induced HPV oncogene repression is linked to the downregulation of cellular factors associated with E6/E7 expression in HPV-positive cancer biopsies. Notably, despite efficient E6/E7 repression, Metformin induces only a reversible proliferative stop in HPV-positive cancer cells and enables them to evade senescence. Metformin also efficiently blocks senescence induction in HPV-positive cancer cells in response to targeted E6/E7 inhibition by RNA interference. Moreover, Metformin treatment enables HPV-positive cancer cells to escape from chemotherapyinduced senescence. These findings uncover profound effects of Metformin on the virus/host cell interactions and the phenotype of HPV-positive cancer cells with implications for therapy-induced senescence, for attempts to repurpose Metformin as an anticancer agent and for the development of E6/E7-inhibitory therapeutic strategies.

show abstract

ASF1B promotes cervical cancer progression through stabilization of CDK9

Cited by 60 publications

References 56 publications

Aberrantly ASF1B Promotes Proliferation and Metastasis of Lung Adenocarcinoma in Vitro Study

Aberrantly ASF1B Promotes Proliferation and Metastasis of Lung Adenocarcinoma in Vitro Study

Comprehensive analysis of pan‐cancer reveals potential of ASF1B as a prognostic and immunological biomarker

Effects of Metformin on the virus/host cell crosstalk in human papillomavirus‐positive cancer cells

Contact Info

Product

Resources

About